Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -10 of 19 Show results per page	View Search Criteria \| Help With Results

Last Modified: 2/16/2007 First Published: 5/23/2005


1.		Phase I/II Pilot Study of Flavopiridol in Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				18 and over				NCI				OSU-04100 OSU-2005C0006, NCI-7002, 7002, NCT00112723

Last Modified: 5/13/2008 First Published: 3/2/2007


2.		Phase I/II Study of Flavopiridol in Patients With Refractory or Recurrent Mantle Cell Lymphoma or Diffuse Large B-Cell Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Biomarker/Laboratory analysis, Treatment				Active				18 and over				NCI				NCI-07-C-0081 NCI-P7040, 7844, NCT00445341

Last Modified: 6/11/2008 First Published: 4/23/2004


3.		Phase II Study of Cisplatin and Flavopiridol in Patients With Advanced Ovarian Epithelial or Primary Peritoneal Cancer ( Group 2 closed to accrual as of 3/10/06)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				NCI				MAYO-MC0261 5876, NCI-5876, NCT00083122

Last Modified: 7/26/2007 First Published: 11/22/2004


4.		Phase II Study of Flavopiridol in Patients With Previously Treated B-Cell Chronic Lymphocytic Leukemia (CLL) or Prolymphocytic Leukemia Arising from CLL

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				NCI				CLLRC-OSU-0491 7000, NCI-7000, NCT00098371, OSU-0491


5.		Alvocidib in Patients With Previously Treated Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia Arising From Chronic Lymphocytic Leukemia (CLL)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				Pharmaceutical / Industry				EFC6663 HMR1275, NCT00464633

Last Modified: 6/16/2008 First Published: 3/10/2008


6.		Phase II Randomized Study of Three Different Induction/Consolidation Chemotherapy Regimens; Carboplatin and Topotecan Hydrochloride Versus Alvocidib, Mitoxantrone Hydrochloride, and Cytarabine Versus Sirolimus, Mitoxantrone Hydrochloride, Etoposide, and Cytarabine in Patients With Relapsed or Refractory Acute Myeloid Leukemia

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Approved-not yet active				18 to 70				NCI				ECOG-E1906 E1906, NCT00634244

Last Modified: 7/26/2007 First Published: 10/1/2002


7.		Phase I Study of Flavopiridol, Irinotecan, and Cisplatin in Patients With Advanced Solid Tumors

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Active				18 and over				NCI				MSKCC-02043 NCI-5700, NCT00046917, 5700

Last Modified: 6/5/2008 First Published: 10/25/2003


8.		Phase I Study of Gemcitabine and Flavopiridol in Patients With Solid Tumors

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Active				18 and over				NCI				DFCI-03110 NCI-6051, NCT00072436, 6051

Last Modified: 7/26/2007 First Published: 3/24/2004


9.		Phase I Study of Flavopiridol, Oxaliplatin, Fluorouracil, and Leucovorin Calcium in Patients With Advanced Solid Tumors

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Active				18 and over				NCI				MSKCC-03146 6365, NCI-6365, NCT00080990

Last Modified: 3/6/2007 First Published: 4/23/2004


10.		Phase I Study of Bortezomib and Flavopiridol in Patients With Recurrent or Refractory Indolent B-Cell Neoplasms

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Active				18 and over				NCI				MCV-MCC-6413 NCI-6413, 6413, NCT00082784

Select All on One Page


					1 2 Next >

| | | | | | | |

A Service of the National Cancer Institute